Jazz's Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Receives the US FDA's Approval for Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Shots:
- The approval is based on clinical data from an ongoing P-II/III JZP458-201 trial evaluating Rylaze in pediatric and adult patients aged ≥1mos. with ALL or LBL who are allergic to the E. coli-derived asparaginase. Rylaze has approved under the RTOR program
- Additionally- recent data from a Children's Oncology Group retrospective analysis in ~8-000 patients showed that the patients without asparaginase treatment due to associated toxicity had lower survival outcomes
- The therapy is expected to be commercially available in mid-July in the US. The FDA has granted ODD to Rylaze for ALL/LBL in June’21 & FTD in Oct’19
| Ref: PR Newswire | Image: Life Sciences IP Review
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com